HOME >> MEDICINE >> NEWS
The Lancet Oncology (TLO)

Billions of dollars are currently being spent on the search for effective drugs that will stop disease before it happens. Advances in genetic testing are providing more opportunities to find out which diseases people are likely to be at risk of developing--but this knowledge has put huge pressure on the medical profession to come up with ways of avoiding disease altogether. This month's leading edge questions the ethical issues involved in chemoprevention and highlights the difficulties in obtaining reliable data from chemoprevention clinical trials. It concludes: "Genetic tests have created a demand for chemoprevention that is threatening to push medicine to its limits; health services could be stretched beyond capacity because they are treating healthy people as well as the sick. To stop this snowball effect it is essential that one simple idea is kept in mind: you can spend all the money in the world on preventive medicine, but when people won't even stop smoking, can it really work?"

STOMACH CANCER - THE LATEST TARGET FOR THE 'MAGIC BULLET'

Gastrointestinal stromal tumours (GISTs) are the most recent cancer type to be targeted by the most effective new drug of recent years--imatinib mesylate. Effective treatment of GISTs has been hindered in the past by their characteristic resistance to conventional chemotherapy and persistent misclassification of these tumours in clinical studies has made pre-2000 data difficult to interpret. However, it is now known that most GISTs contain a mutation in the KIT tyrosine kinase, which means they are an ideal target for imatinib. In their review, Heikki Joensuu and colleagues discuss the recent advances in understanding of these difficult-to-treat tumours and discusses the impact of imatinib on outcome for patients with GISTs. The authors conclude that imatinib "has provided physicians with a well-tolerated and highly effective therapeutic option for a disease for which no systemic therapy existed previously".
'"/>

Contact: Richard Lane
richard.lane@lancet.com
44-207-424-4949
Lancet
30-Oct-2002


Page: 1 2

Related medicine news :

1. The Lancet calls for the creation of a world institute for risk evaluation
2. The Lancet calls for creation of Intl Commission on Global Responses to Complex Emergencies
3. Majority of authors retract 1998 Lancet paper-Lancet editor points to implications
4. The Lancet Infectious Diseases (TLID)
5. The Lancet Neurology November press release
6. Lancet readers to join WHO election debate
7. The Lancet Oncology press release
8. The Lancet Neurology October press release
9. The Lancet neurology press release
10. The Lancet Neurology press release
11. The Lancet Oncology (TLO) and the Lancet Infectious Diseases (TLID)

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/5/2018)... Pa. (PRWEB) , ... October ... ... the award-winning, multi-channel medical broadcasting company delivering education to healthcare professionals through ... web and mobile destination designed exclusively for rheumatologists. , "This is ...
(Date:10/3/2018)... MILWAUKEE (PRWEB) , ... October 03, 2018 , ... ... first mobile clinical tool to allow OB/GYNs to remotely monitor their pregnant patients’ ... the Froedtert & Medical College of Wisconsin health network (MCW). Patients who choose ...
(Date:10/3/2018)... ... October 03, 2018 , ... Tranquil Care Hospice, the only ... been awarded CHAP (Community Health Accreditation Partner, Inc.) Accreditation under the CHAP Hospice ... deemed to meet the Medicare Conditions of Participation and is certified as a ...
(Date:10/3/2018)... ... October 03, 2018 , ... Intellimed ... – a web-based tool that provides turnkey strategic direction based upon the ... and marketing groups can quickly query diagnostic (DX) and procedure (PX) codes ...
(Date:10/2/2018)... ... 02, 2018 , ... Today, AngelMD is announcing the close of a $594,000 ... total $3.4 million round that has now been closed by the company. , ... However, the status quo for PICC equipment has an inherent problem -- the potential ...
Breaking Medicine News(10 mins):
(Date:10/13/2018)... , ... October 12, 2018 , ... ... on July 7, 1987 which was used in the Lockheed F22 Aircraft. Today, ... between controlled and uncontrolled AF-Arrhythmia, which can lead to sudden cardiac death (SCD). ...
(Date:10/13/2018)... ... October 13, 2018 , ... In the world of contract ... massive brand after another. 2018 has been a game-changing year for Ion Labs ... a large role in the growth. Ion Labs attributes its growth to its responsiveness ...
(Date:10/11/2018)... ... October 11, 2018 , ... ... announced today that it has completed the strategic combination of RevSpring and ... patient revenue cycle engagement, billing, and payments solutions generating over one billion ...
Breaking Medicine Technology:
Cached News: